HomeQuestion

Do you use different follow-up intensity and discontinuation criteria for mixed-pattern (R 2–5) versus cholestatic-pattern (R <2) DILI?

Join the Discussion

Discuss the cases and questions guidelines don't cover.

Related Questions

How do you approach HCC screening in patients with advanced fibrosis e.g., F3 on FibroScan?

How do you pragmatically approach a conversation about "liver detox"/"liver cleansers" when patients bring up this topic?

In suspected antibiotic-associated cholestatic DILI with jaundice and no obstructing lesion on MRCP, what specific clinical or laboratory trajectory triggers you to proceed to early liver biopsy to evaluate for evolving vanishing bile duct syndrome rather than continued close outpatient monitoring?

For checkpoint inhibitor–associated cholangitis/secondary sclerosing cholangitis, what is your clinically actionable corticosteroid-trial algorithm (including which imaging, histologic, and biochemical response features define steroid responsiveness vs futility)?

What minimum clinical phenotype would make you order targeted cholestasis-gene sequencing (e.g., ABCB11/ABCB4/ATP8B1) in severe or prolonged cholestatic DILI because the result would meaningfully change management?

Evidence Meets Expertise

For Physicians

Mednet AI
Community

Company

About
Careers
Publications
Blog

Support

FAQs
Code of Conduct
AI Community Guidelines
Contact Us
Programs

Legal

Privacy Policy
Terms of Service

© 2026 Mednet Inc. All rights reserved.